Karius, Capstone Health widen access to liquid biopsy test

2022 06 09 19 27 4366 Cell Gene Therapy Dna 400

Karius is collaborating with a group purchasing firm to broaden access to a test that can rapidly detect more than 1,000 infectious disease pathogens in a blood sample.

According to Karius, the new partnership will also broaden access to microbial cell-free metagenomics technology used in the liquid biopsy-based, lab-developed test.

The tool uses artificial intelligence (AI) to rapidly parse pathogen DNA fragments found in a patient's blood sample.

Doctors at more than 265 Capstone member hospitals in the U.S. will be able to order the test for patients harboring hard-to-diagnose infections, Karius said, adding that U.S. institutions including children's hospitals and transplant centers are already using the test.

Page 1 of 13
Next Page